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ABSTRACT 
Two new psychoactive substances, namely 4-methylmethcathinone (mephedrone) and 5,6-
methylenedioxy-2-aminoindane (MDAI) were analysed with a novel combination of 
microcrystalline tests followed by Raman micro-spectroscopy to facilitate their absolute 
identification. The discrimination power of the proposed combination was successfully 
demonstrated through the analysis of the positional isomers 2- and 3-methylmethcathinone. 
The addition of mercury dichloride as a microcrystalline test reagent produced specific 
microcrystals of each tested analyte. The robustness of the method was evaluated in the 
presence of common cutting agents (caffeine and benzocaine) as well as on street samples.  
The crystal lattice structures of mephedrone, 2-methylmethcathinone and MDAI mercury 
dichloride microcrystals were determined by single crystal X-ray diffraction. This confirmed the 
presence of both drug and reagent together in the lattice and accounts for the distinct habit of 
the observed microcrystals. 
Raman spectra of the formed microcrystals differed from those obtained from their standard 
salt form by loss and/or gain of some vibrational modes. Particularly important was the 
appearance of the mercury chloride link to each tested drug molecule which showed as strong 
bands at low wavenumbers. Its presence was corroborated by its detection in the crystal lattice. 
It was therefore concluded that microcrystalline testing followed by Raman micro-spectroscopy 
satisfies the technique combination requirement for psychoactive substances recommended by 
the Scientific Working Group for the Analysis of Seized Drugs (SWGDRUG) and provides a rapid 
and cheap analysis route. 
The proposed technique combination also aids the development of new microcrystalline tests 
as it allows for confirmation of the uniqueness of the developed microcrystals almost in-situ 
rather than growing single crystals for often long periods of time needed for single crystal X-ray 
diffraction analysis. 
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INTRODUCTION 
Microcrystalline testing in forensic drug analysis is a rapid and cheap micro-chemical 
confirmation method for the identification of psychoactive substances. Microcrystals are 
crystals which develop to a size between 1 and 1000 µm, and are formed between a substance 
(e.g. a drug of abuse) and a suitable reagent (e.g. transition metal ions). Compounds are usually 
dissolved in water and crystals develop by solvent evaporation or direct precipitation[1]. The 
habit of the formed microcrystals obtained from an unknown sample is compared to that of 
microcrystals produced with reference standards. Microcrystals in forensic drug analysis can be 
classed as addition products or mixed crystals as both sample and reagent are responsible for 
the crystal development[2].  
The Scientific Working Group for the analysis of seized drugs (SWGDRUG) categorises analytical 
techniques according to their maximum potential discriminating power from A to C. Category A 
holds the highest discrimination power and includes amongst others mass spectrometry (MS) 
and vibrational spectroscopy, while category C holds the lowest with techniques such as colour 
tests and UV/FL spectroscopy[3]. The working group has positioned microcrystalline tests into 
category B alongside chromatography techniques meaning that they hold a certain 
discriminating power but do not provide structural information and thus must be used in 
conjunction with another, ideally more powerful technique such as those from category A to 
achieve unequivocal identification. 
Widely available vibrational spectroscopy techniques such as Fourier transform infrared (FTIR) 
or Raman spectroscopy are popular category A choices for drug samples in solid and liquid 
form, and have been proven useful in the discrimination of substituted cathinone isomers and 
other psychoactive substances[4–7]. It is of advantage for drug analysis that Raman spectroscopy 
can be used in the presence of water and that it can be interfaced with microscopy. Especially 
noteworthy is the use of surface enhanced Raman scattering (SERS) which was demonstrated to 
give reliable qualitative and quantitative results when psychoactive substances were analysed 
[8–10].  
Street drugs are often cut with diluents, for example legal high samples purchased online or in 
head shops are often cut with caffeine or benzocaine[11]. These cutting agents can make 
identification difficult using spectroscopy techniques such as FTIR or Raman spectroscopy if no 
separation of the ingredients has been done beforehand, much so that SWGDRUG downgrades 
vibrational spectroscopy from category A to B if used on mixtures[3]. In the combined spectra 
obtained identification features can be obscured and therefore a separation of analytes is 
required beforehand to achieve absolute identification[12].   
Favoured separation techniques are gas and liquid chromatography (GC and LC) which are 
typically hyphenated with MS[11,13–16]. However, the hyphenation of chromatography 
techniques with non-mass spectral detectors has been successfully investigated over the last 
years. GC with infrared spectroscopy (GC-IRD) has recently been used to analyse novel 
psychoactive substances and enabled differentiation between regioisomers of 
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methamphetamine, piperazines, phenethylamines and cathinones[17–22]. Furthermore, 
electrochemistry techniques offer a rapid yet very selective alternative for the detection of 
psychoactive substances and have been proven particularly useful in the analysis of novel 
psychoactive substances, either using electrochemical sensors on their own or paired with 
chromatography[23–27]. 
Purification methods such as liquid-liquid (LLE) and solid phase extraction (SPE) are performed 
prior to analysis and constitute a semi-specific separation process. Crystallisation is a liquid-
solid extraction (LSE) which is commonly used by organic chemists to purify synthesised 
substances in order to remove undesired precursors, by-products or other impurities. 
Microcrystalline testing of psychoactive substances therefore qualifies as a type of extraction 
technique.  
Although more sophisticated instrumental techniques are available, microcrystalline testing 
remains to play an important role in forensic drug analysis, for example in the recently 
published compendium by the McCrone Research Institute, USA which received Government 
funding to update and modernise existing tests[28]. The use of the technique is also supported 
by the United Nations Office on Drugs and Crime (UNODC) who added microcrystalline tests as 
part of their recommended methods for analysis of a variety of compounds (e.g. cathinones, 
piperazines, amphetamines and cocaine), as does the American Society for Testing and 
Materials (ASTM) for Forensic Science who regularly publishes guidelines for forensic scientists 
including standard procedures on carrying out microcrystalline tests[29–35].  
With the emergence of novel psychoactive substances the search for discriminatory techniques 
which can distinguish between a variety of naturally and synthetically produced isomers, 
microcrystalline testing offers a valuable alternative analytical technique[36].  
 
The presented methodology of microcrystalline tests followed by Raman micro-spectroscopy is 
a proof-of principle investigation into the discrimination power of microcrystalline tests for the 
analysis of NPS and their isomers as well as cutting agents present in mixtures.  This constitutes 
a novel strategy in drug analysis using microcrystalline tests as both identification tests and 
extraction tool. Single crystal X-ray diffraction (SC-XRD), a SWGDRUG category A technique, was 
chosen as the validation method as it has the power to detect molecules and their arrangement 
within a crystal lattice. Historically, microcrystalline tests have been developed without any 
conclusive evidence that the drug molecule was incorporated into the crystal lattice, however 
more recently it has been the customary way of establishing that microcrystals are forming out 
of a mix of drug and reagent solution, and indeed contain the drug molecule combined with the 
microcrystalline test reagent proving that the drug molecule as a whole is responsible for the 
interpretable result of the test, unlike solely targeted moieties as can be seen in colour tests[37–
40]. Indeed, the combination of several reagents in flow-chart analysis style can lead to the 
identification of groups of compounds as the technique often only relates to a functional group 
rather than being specific for individual molecules[41–45].  
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This study utilises a series of compounds, namely 4-methylmethcathinone (“mephedrone”) and 
its positional isomers 2- and 3-methylmethcathinone as well as 5,6-
methylenedioxyaminoindane (“MDAI”). Mephedrone and MDAI have been found in ‘legal high’ 
products in the last years[46]. Mephedrone is a cathinone derivative with effects similar to 
stimulants such as cocaine and amphetamine[47]. It was controlled in the UK in 2010 under the 
Misuse of Drugs Act 1971 (S.I. 2010/1207). MDAI was discovered in the 1990’s by the Nichols 
group and is said to mimic the psychoactive behaviour of 3,4-
methylenedioxymethamphetamine (MDMA) and is currently not scheduled in the UK[48,49].  
The proposed methodology was applied to both pure drug standards and model mixtures with 
common cutting agents as well as ‘legal high’ products in order to evaluate its robustness and 
to validate the combination of microcrystalline testing with Raman micro-spectroscopy for 
absolute identification of NPS. 
 
 
EXPERIMENTAL 
 
Chemicals 
Mephedrone (4-methylmethcathinone; 4-MMC) and mercury dichloride were purchased from 
Sigma-Aldrich (Gillingham, UK); 2-methylmethcathinone (2-MMC), 3-methylmethcathinone (3-
MMC), and 5,6-methylenedioxy-2-aminoindane freebase (MDAI) were from LGC Standards 
(Teddington, UK). Hydrochloric acid (≈ 37%, analytical reagent grade) was purchased from 
Fisher (Loughborough, UK). All water used was deionised to > 15 MΩ resistance.  
Between November 2010 and April 2012 eight samples of MDAI products were purchased 
online from various vendors. One sample containing mephedrone was purchased online in 
March 2010; another sample was submitted anonymously to the University of Lincoln analytical 
laboratories in summer 2012. 
 
Preparation of microcrystalline tests on slides 
Microcrystalline tests were carried out on standard microscope glass slides (Fisher) and used as 
obtained. 5 µL of each drug and reagent solution (10 g L-1 H2O) were mixed directly on the slides 
and crystallisation was systematically encouraged by moving a pipette tip gently around the 
drop for a few seconds. Crystal development was observed under low and high magnifications 
using calibrated transmitted light microscopy set for Koehler illumination at 400x overall 
magnification. Images were captured using a Canon EOS Rebel T2i digital SLR camera fitted with 
a Meiji Techno adapter ring, camera attachment and 1.9x magnification photo-eye piece. 
All experiments were carried out under standard laboratory conditions of temperature, 
pressure and humidity without any variation in microcrystal development. 
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Raman analysis 
Raman analysis was performed on a Horiba Jobin Yvon LabRAM 300 with a 300 mm focal length 
spectrometer, equipped with a BX41 confocal microscope attachment from Olympus and fitted 
with a green laser at 532 nm from Laser Quantum. The 50x objective was used for all 
spectroscopy analysis. The laser power was measured with a handheld LaserCheck from 
Coherent (Dieburg, Germany). Settings such as scan range, laser power (10.4 to 0.001 mW), 
hole (300 µm), slit (100 µm) and exposure time were optimised for each microcrystal type. Raw 
data was made up of spectra recorded in two cycles; a minimum of three replicate spectra (raw 
data) were recorded for each substance.  
 All spectra were processed using the LabRAM associated LabSPEC software (Version 5.64.15, 
2008) by performing baseline correction and normalisation. Raman group wavenumbers were 
assigned using text book literature[50]. 
 
Preparation of microcrystals for SC-XRD 
Mephedrone microcrystals were grown by mixing 100 µL of aqueous solutions of 10 g L-1 of 
each mephedrone and mercury dichloride in a round glass cuvette (X Systems from Abbott 
Laboratories Wiesbaden, Germany) which was then covered with parafilm and pierced once 
with a needle to avoid dust contamination but allow slow evaporation. Cuvettes were stored 
away from vibrations in order to not disturb the crystal formation. Crystals were large enough 
to harvest after approx. 7 days with a length of approx. 1 mm. Crystals developed in complex 
paddle wheel structures which were separated using Hampton Research micro tools (California, 
USA).  
Microcrystals of 2-MMC were grown by depositing 10 µL of aqueous solutions (10 g L-1) of drug 
and mercury dichloride on a slide. Nucleation was assisted by gently mixing the content of the 
drops with a pipette tip. Crystals ready for harvesting developed after approx. 15 min. 
 
MDAI crystals were grown by filling a 0.6 mm ID flat capillary tube of approx. 10 mm length 
(VitroCom, CM Scientific, Shipley, UK) with 50 µL of aqueous solutions (10 g L-1) of MDAI 
hydrochloride and mercury dichloride. MDAI hydrochloride was prepared from the LGC 
freebase standard by adding 10 µL of concentrated hydrochloric acid to 1 mL of water with 10 
mg suspended MDAI freebase; the suspension was vortexed until dissolved (≈ 10 s). Nucleation 
to form crystals was assisted by inserting a nickel chromium wire (Consolidated Electronic Wire 
& Cable, www.conwire.com) into the tube and gently moving it around. Microcrystals of 
approx. 100 µm in diameter formed within one hour. Crystals were harvested by observing the 
tube under a Meiji ML 5000 microscope (Axbridge, UK) at low magnification. The tube was 
opened with a diamond pen and suitable crystals were transferred onto a glass slide using 
micro tools. 
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All single crystals were pushed into silicon oil (Fisher, UK) and mounted onto a nylon CryoLoop 
of 20 µm diameter (Hampton Research) for analysis by SC-XRD on an Agilent Technologies, 
Xcalibur, Sapphire3 equipped with a fine-focus sealed molybdenum X-ray tube and Oxford 
Cryostream. The structure was solved and refined using the programs SHELXS-97 (Sheldrick, 
1990) and SHELXL-97 (Sheldrick, 1997) respectively. The program X-Seed (Barbour, 1999) was 
used as an interface to the SHELX programs.   
 
As crystals for single crystal XRD were grown considerably fast to represent best those obtained 
from microcrystalline tests in the field they were small and undergrown which resulted in poor 
X-ray diffraction. 
 
 
 
RESULTS AND DISCUSSION 
 
Microcrystalline tests for the detection of both mephedrone (4-MMC) and MDAI have been 
developed by Elie et al. using mercury dichloride as reagent[46]. Mephedrone forms paddle-
wheel clusters of square-cut blades while MDAI hydrochloride produces trapezoidal blades 
(Figure 1 and 2); both microcrystalline tests develop within a few minutes. 
Microcrystals formed for 2-MMC as flat blades and rods, sometimes as smaller clusters of 
serrated plates with varying angles and thickness from the edge of the drop after 15 minutes 
and 3-MMC produced amorphous crystalline material originating from a point at the solvent 
front after approx. 20 minutes (Figure 1). Subsequently, microcrystalline tests can be used to 
distinguish between the positional isomers 2-, 3- and 4-MMC although absolute identification 
can currently only be achieved for the latter. To the best of the authors’ knowledge the 
distinction of MMC positional isomers by microcrystalline test has not been reported 
previously. 
Microcrystals and salt crystals of reference substances behaved differently upon exposure to 
the 532 nm laser. Microcrystals did not withstand laser intensities larger than 1.01 mW for the 
duration of an analysis of 20 s for MDAI and 60 s for mephedrone, respectively, whereas the 
reference material did not exhibit any changes. Upon impact of the green laser, microcrystalline 
structure was locally destroyed which inhibited the amplification of Raman scattering. 
Subsequently, the range for analysis was chosen to be between 200 and 1800 cm-1 in order to 
minimise laser exposure of the fragile microcrystals by focussing on the fingerprint region only. 
The measurement range for MDAI crystals was further limited to 200- 1690 cm-1 as it meant 
that the spectrometer of the dispersive Raman did not need repositioning during the analysis 
thus significantly decreasing the run time and therefore preserving the integrity of the 
microcrystals during analysis. 
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The Raman spectra of each methylmethcathinone isomer and its respective mercury dichloride 
microcrystal displayed band shifts and intensity differences caused by the coupling of vibrations 
of neighbouring molecules in the newly formed crystal lattices compared to the standard salts 
(Figure 1)[51,52].  
 
The solid state mephedrone microcrystal determined by SC-XRD has a monoclinic C 2/c space 
group which consists of a (Hg2Cl4) unit with four mephedrone molecules associated via short 
contacts between one amino group and two chlorides (Fig S1i). These units are arranged in 
translational symmetry along the c-axis. The metal-halide chains form a reagent framework 
which is interlaced with mephedrone molecules. It is assumed that the framework expands 
along the c-axis more rapidly while assembly along a- and b-axes are less favoured due to the 
sterical hindrance of protruding mephedrone molecules. This expansion could subsequently 
result in the observed rectangular plate [4-MMC HgCl2] microcrystals. 
In comparison the crystal lattice of [2-MMC HgCl2] has a triclinic P-1 space group. However, 
similar to [4-MMC HgCl2] it also presents two cathinone-derivative molecules linked via short 
contacts to mercury dichloride units in the centre of the unit cell and short contacts are 
established between amino groups and chlorides (Fig S1ii). Mercury dichloride forms a parallel 
frame along the c-axis enclosing 2-MMC molecules with phenyl groups facing towards the 
centre and away from the polar mercury chloride frame thus strengthening the crystal structure 
by π-π stacking in parallel-displaced configuration. 
 
The incorporation of mercury reagent and drug molecule into one crystal lattice was 
corroborated by the observation of strong vibrational modes in the lower wavenumber region 
of 200-300 cm-1 indicating the presence of a mercury dichloride network in the formed crystals. 
Wavenumber shifts of the secondary aliphatic amine wagging vibrations in the region of 750-
710 cm-1 were observed when 2-MMC and 3-MMC were crystallised with mercury dichloride. 
This band appears to have shifted to higher wavenumbers in the 4-MMC material. Bands 
around 840-850 cm-1 which could only be seen in 2-MMC and [2-MMC HgCl2] were assigned to 
disubstituted benzene ring out-of-plane deformation vibrations. Aromatic =C-H in-plane 
deformation vibrations between 1050-1200 cm-1 remained largely unchanged for all species. 
Furthermore, the addition of metal reagent in the crystal lattice induced intensity changes of 
the -C=C- aromatic in-plane deformation vibrations between the cathinone isomers and their 
respective microcrystals. Shifts to lower wavenumbers of the α,β-unsaturated keto-group were 
observed in the case of 2-MMC and 3-MMC and their microcrystals but remained unchanged in 
4-MMC and [4-MMC HgCl2]. 
The morphology of crystals formed between 3-MMC and mercury dichloride [3-MMC HgCl2] did 
not allow analysis by SC-XRD. However, the presence of the mercury chloride band in the 
Raman spectra allowed concluding that a similar network of reagent interlinked with 3-MMC 
molecules is present in the obtained crystalline material. 
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The MDAI standard was converted from the commercially available freebase to the 
hydrochloride salt (HCl) as street samples were found to solely contain the hydrochloride salt 
variety[46]. The MDAI freebase standard produces different microcrystals to the hydrochloride 
salt by forming flat serrated blades of varying dimensions while the salt developed into 
trapezoidal blades which were overall smoother on the surface but smaller than the freebase 
crystals[46]. Controls of the MDAI HCl salt were compared to microcrystals obtained with the 
mercury dichloride reagent and MDAI salt (Figure 2).  
 
The MDAI base lattice determined by SC-XRD has a primitive centrosymmetric orthorhombic 
Pnma space group which consists of one MDAI molecule, and one mercury cation surrounded 
by three chloride anions in the form of (HgCl3)- (Fig S2). The approximately planar MDAI 
molecule is positioned at an angle away from mercury dichloride but its functional amino group 
which is hinged out of plane is cradled between three chloride atoms of two transversely 
situated (HgCl3)- units. Mercury dichloride forms a straight chain of bonded (HgCl3)- units along 
which the MDAI molecules arrange themselves. The units of two MDAI molecules associated to 
(HgCl3)- are packed in translational symmetry along the c-axis forming a mercury dichloride 
spine. The MDAI-Hg-MDAI unit then stacks in twofold rotation along the b-axis. The fastest 
growth is assumed to be along the c-axis where strong bonded mercury dichloride chains 
develop with MDAI molecules assembling alongside it. The b- and a-axes may determine width 
and depth of the microcrystals with slower packing of MDAI molecules next to each other 
potentially resulting in the observed blades. 
 
Generally, Raman bands in the [MDAI HgCl2] spectra appeared more pronounced than those in 
the MDAI HCl spectra (Figure 2). The presence of mercury dichloride in the crystal lattice was 
characterised by a broad band at around 250 cm-1. The band at 714 cm-1 in the MDAI salt 
spectrum was assigned to -C=C- cis-di-substituted alkene deformation vibrations. Coupling of 
vibrations caused this band to split into a triplet with bands at 667 cm-1, 699 cm-1 and 724 cm-1 
in the [MDAI HgCl2] microcrystals. Amine deformation vibrations caused a band at 780 cm-1 in 
the MDAI salt while the corresponding band in the [MDAI HgCl2] microcrystals shifted to 799 
cm-1.  A single band at 861 cm-1 in the MDAI salt due to –C-O-C- aliphatic ether symmetric 
stretching vibrations and tetra-substituted aromatic ring vibrations appeared as a doublet in 
the microcrystal spectra with bands at 837 cm-1 and 860 cm-1, respectively. 
Between 1100 and 1400 cm-1 bands caused by –C-O-C- and =C-O-C- ether symmetric and 
asymmetric stretching vibrations as well as methoxy C-O stretching vibrations appeared in both 
salt and microcrystal species, however significant differences in intensity were observed: some 
weak or nearly absent in the MDAI salt spectra yet strong in the [MDAI HgCl2] microcrystal 
spectra. The intensity differences were more prominent in repeats of analysed microcrystals yet 
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not consistent allowing to conclude that relative crystal orientation on the slide to be the cause 
of this phenomenon[52]. 
 
MDAI microcrystals formed with mercury dichloride do not have hydrogen bonds between 
metal reagent and drug molecule. The arrangement of drug-originating hydrogen-bond donor 
amine groups towards a mercury dichloride reagent spine is based on van-der-Waal’s forces 
which are thermodynamically more favourable than interactions between the parent 
molecules, hence allowing the rapid growth of microcrystals rather than a single substance re-
crystallisation from the solvent[53,54]. However, mephedrone contacts between amino group 
and chloride anion had comparable bond lengths to those reported by Steiner on primary 
ammonium donor groups with chloride anion acceptors indicating that hydrogen bonding is 
linking the metal framework within the microcrystal[55].  
 
To demonstrate the power of the combination of techniques test mixtures of solid NPS and 
cutting agent were prepared in ratios of 1:3; 1:1 and 3:1 and subsequently analysed using 
microcrystalline test and Raman micro-spectroscopy. As well as MDAI and mephedrone, 
caffeine also crystallises readily with mercury dichloride by forming long needles which usually 
appear at the edge of the drop[1,46]. Benzocaine does not form distinct crystals with mercury 
dichloride but can precipitate as amorphous solid (Figure 3). 
All tested model mixtures developed microcrystals of the respective NPS. All mixtures 
containing caffeine produced the related microcrystals of needles; however, in some cases the 
caffeine needles appeared distorted by the presence of MDAI[46].  
When mephedrone was present, caffeine needles always developed after the mephedrone 
crystals which were at that point in time partly consumed and developed broken edges and 
irregular surfaces. This affected the quality of Raman spectra by creating drifting and noisier 
baselines. However, this did not affect the identification of mephedrone from the spectra since 
effects of these physical phenomena were greatly reduced by applying baseline correction. 
Altogether, the Raman spectra of NPS microcrystals were not changed by the presence of a 
cutting agent, neither when present as another microcrystal (e.g. caffeine) nor dissolved 
seemingly un-associated in the solvent (e.g. benzocaine). The similarity of Raman spectra 
between pure standards as well as those mixed with adulterants can be seen in Figure 3. Raman 
spectra obtained from microcrystals developing alongside the precipitate of benzocaine and 
mercury dichloride are not shown as they did not differ from those present in this paper. 
Finally, eight internet purchased MDAI products and two legal high samples containing 
mephedrone were analysed using the microcrystalline test/ Raman micro-spectroscopy 
combination. All MDAI products produced trapezoidal blades confirming the presence of the 
MDAI hydrochloride salt. Mephedrone-reagent microcrystals developed as expected with 
identical habit to that exhibited by the standard. Raman spectra of microcrystals obtained from 
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“legal high” products matched those obtained from standards without any shifts or other band 
changes. 
 
 
CONCLUSION 
 
Two microcrystalline tests were investigated in order to validate that the combination of 
microcrystalline testing followed by Raman micro-spectroscopy hold the power for unequivocal 
identification of NPS. The development of microcrystals represents an extraction of active 
ingredients by forming specific and unique crystals for each compound. The crystal lattice 
structures of both MDAI and mephedrone microcrystals as well as crystals formed between the 
structural isomer 2-MMC and mercury dichloride were solved using single crystal X-ray 
diffraction. All NPS molecules were found in their respective microcrystal confirming that the 
drug molecule as a whole is responsible for the formation of a specific microcrystal. It also 
confirms that microcrystalline testing is a solid identification method as it produces specific 
crystals containing exclusively drug and reagent proving the uniqueness of the crystal habit 
under set conditions, and that a separation of the analyte from the matrix took place. Finally, it 
confirms that the specific use of the mercury dichloride reagent enables rapid, cheap and 
definite discrimination between 2-, 3- and 4-MMC. 
Although the lattice structures of crystals formed between 3-MMC and mercury dichloride 
could not be determined the presence of the metal-chloride band in associated Raman spectra, 
it still allows to conclude that the reagent was incorporated in the crystal lattice which in turn 
strengthens the argument for habit comparison of microcrystalline testing given that the 
observed crystals varied greatly in habit for the analysed cathinone isomers. Subsequently, the 
incorporation of metal reagent as well as presence of the psychoactive analyte can be easily 
proven via Raman micro-spectroscopy. 
The combination of microcrystalline testing and Raman micro-spectroscopy therefore presents 
a robust analytical strategy for routine analysis which satisfies the requirements set by 
SWGDRUG of using two independent techniques while being quick and simple to set up. It also 
potentially removes the issue of SWGDRUG downgrading vibrational spectroscopy from 
category A to B when used on mixtures as the microcrystalline test acts as an extraction tool for 
Raman spectroscopy as well as an identification method in its own right. 
The robustness of the proposed combination of analytical techniques was established by 
successfully identifying psychoactive compounds in model mixtures and street samples. 
Raman spectra obtained from microcrystals exhibited some band differences to those of 
microcrystals formed with the pure salts. This can be seen as a confirmation step for the 
analysed NPS similar to transformed fragmentation patterns in mass spectrometry when 
derivatisation of the analyte is carried out. The comparison of pure standard, standard-
microcrystal and sample-microcrystal gives a unique set of bands resulting in absolute 
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confirmation of the identification result obtained by microcrystalline testing. Spectra of 
microcrystals formed from drug standards could subsequently be entered in a database 
accompanied by images of crystal habits to create a searchable portfolio for routine analysis. 
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Figure 1 
Chemical structures of 2-, 3- and 4-MMC depicted with corresponding microcrystals formed upon 
addition of mercury dichloride. Raman spectra of A 2-MMC HCl (1), B [2-MMC HgCl2], C 3-MMC HCl (2), 
D [3-MMC HgCl2], E 4-MMC HCl (3) and F [4-MMC HgCl2] obtained with 532 nm laser at 1.0-5.2 mW 
power, 300 μm confocal hole, 100 μm slit width, 2 cycles and between 5 to 30 seconds exposure time. 
All spectra have been baseline corrected and normalised. Table contains tentative band assignment with 
the following abbreviations: def… deformation; vib… vibration; sym… symmetric; asym… asymmetric; 
str… stretching. 
 
 
Figure 2 
Chemical structure of MDAI depicted with corresponding microcrystal formed upon addition of mercury 
dichloride. Raman spectra of A MDAI HCl and B [MDAI HgCl2] obtained with 532 nm laser at 1.0-10.4 
mW power, 300 μm confocal hole, 100 μm slit width, 2 cycles and 10 seconds exposure time. All spectra 
have been baseline corrected and normalised. Table contains tentative band assignment with the 
following abbreviations: def… deformation; vib… vibration; sym… symmetric; asym… asymmetric; str… 
stretching. 
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Figure 3 
Comparing Raman spectra obtained from pure drug-reagent microcrystals of 4-MMC and MDAI to those 
obtained when the adulterant caffeine was present in the mix as well as to street samples of 4-MMC 
and MDAI, respectively, with 532 nm laser at 1.0-5.2 mW power, 300 μm confocal hole, 100 μm slit 
width, 2 cycles and between 5 to 30 seconds exposure time. All spectra have been baseline corrected 
and normalised. Raman spectra A [4-MMC HgCl2] and F [MDAI HgCl2] correspond to the standard 
substance without added adulterants; Raman spectra B, C and D are a result of microcrystals obtained 
when 4-MMC, and G, H and I when MDAI were mixed with caffeine at ratios of 1:3, 1:1 and 3:1, 
respectively. Raman spectra E and J correspond to microcrystals obtained from street samples of 
mephedrone and MDAI, respectively. Depicted microcrystals were obtained from mixtures of drug and 
adulterant at a ratio of 1:1 and correspond to (1) [4-MMC HgCl2] (i) developing alongside [caffeine HgCl2] 
microcrystals (ii); (2) [4-MMC HgCl2] (i) developing in the presence of benzocaine precipitate (no Raman 
spectra shown); (3) [MDAI HgCl2] (iii) developing alongside [caffeine HgCl2] microcrystals (ii); (4) [MDAI 
HgCl2] (i) developing in the presence of benzocaine precipitate (no Raman spectra shown). Crystals were 
observed under 40x magnification. 
 
 21 
 
Fig S1 
Unit cell structure for (i) [4-MMC HgCl2] and (ii) [2-MMC HgCl2] obtained by single crystal X-ray 
diffraction. Reagent atoms and functional groups have been annotated. 
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Fig S2 
Unit cell structure for [MDAI HgCl2] obtained by single crystal X-ray diffraction. Reagent atoms and 
functional groups have been annotated. 
 
 
 
